Uri Lopatin

Uri Lopatin

Chief Executive Officer at
Ukko Inc.
54 year
Health Technology
Consumer Services
Finance

Profile

Uri A. Lopatin was the founder of Assembly Pharmaceuticals, Inc., founded in 2012, serving as Chief Medical Officer & VP-Research & Development.
Dr. Lopatin was the founder of Assembly Biosciences, Inc., founded in 2005, serving as Scientific & Strategic Advisor from 2019 to 2022.
Dr. Lopatin was the founder of Pardes Biosciences, Inc., founded in 2020, serving as Director from 2022 to 2023.
Dr. Lopatin is currently Chief Executive Officer at Ukko, Inc. since 2024 and Operating Partner at Khosla Ventures LLC since 2023.
Former positions include Director-Clinical & Translational Research at Gilead Sciences, Inc. from 2010 to 2012 and Associate Director at Schering-Plough Research Institute from 2007 to 2008.
Education includes graduate and undergraduate degrees from Cornell University in 1994, a graduate degree from New York University in 2003, a graduate degree from UW Medicine in 2001, a doctorate from New Jersey Medical School in 2000, and a graduate degree from National Institutes of Health in 2006.

Uri Lopatin active positions

CompaniesPositionStart
Private Equity Investor 2023-07-31
Chief Executive Officer 2024-10-31

Former positions of Uri Lopatin

CompaniesPositionEnd
PARDES BIOSCIENCES, INC. Founder 2023-08-29
ASSEMBLY BIOSCIENCES, INC. Founder 2022-02-28
GILEAD SCIENCES, INC. Corporate Officer/Principal 2012-08-31
Private Equity Investor 2008-03-31
Founder -
See the detail of Uri Lopatin's experience

Training of Uri Lopatin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

82

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Consumer Services

Consumer Services

Finance

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!